Patents Assigned to JUNMENG BIOSCIENCES CO., LTD.
  • Publication number: 20240117043
    Abstract: The present disclosure provides a bispecific antibody including a binding domain that binds to CD112R and a binding domain that binds to TIGIT, and the binding domain that binds to CD112R includes: HCDR1, HCDR2 and HCDR3 of the amino acid sequence set forth in SEQ ID NO: 1, and/or LCDR1, LCDR2 and LCDR3 of the amino acid sequence set forth in SEQ ID NO: 2; and the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined according to the Kabat, IMGT, Chothia, AbM or Contact numbering system. The present disclosure further provides a polynucleotide encoding the antibody, an expression vector, a host cell and a method for expressing and purifying the antibody, a pharmaceutical composition including the antibody of the present disclosure, and use of the bispecific antibody for treating cancer.
    Type: Application
    Filed: August 4, 2023
    Publication date: April 11, 2024
    Applicants: SHANGHAI JUNSHI BIOSCIENCES CO., LTD., SUZHOU JUNMENG BIOSCIENCES CO., LTD.
    Inventors: Dandan LIU, Jinwei ZHOU, Yuehua ZHOU, Jing ZHANG, Sheng YAO, Hui FENG, Hui LIU, Hongchuan LIU, Li LI, Qiang ZHAO
  • Publication number: 20240067720
    Abstract: A stable anti-TIGIT antibody pharmaceutical composition and an application thereof. The pharmaceutical composition includes a buffer solution, and an anti-TIGIT antibody or an antigen-binding fragment thereof. The anti-TIGIT antibody or the antigen-binding fragment thereof includes HCDR1, HCDR2, and HCDR3 having amino acid sequences as respectively represented by SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, and LCDR1, LCDR2, and LCDR3 having amino acid sequences as respectively represented by SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6. The pH of the pharmaceutical composition is about 5.0-6.5.
    Type: Application
    Filed: January 14, 2022
    Publication date: February 29, 2024
    Applicants: SHANGHAI JUNSHI BIOSCIENCES CO., LTD., SUZHOU JUNMENG BIOSCIENCES CO., LTD.
    Inventors: Peixiang LIU, Hongchuan LIU, Jing ZHANG, Qiang ZHAO, Hui FENG
  • Publication number: 20220363754
    Abstract: Provided are antibodies that bind specifically to TIGIT or antigen binding fragments of the antibodies and a composition thereof. Also provided are a nucleic acid molecule coding the antibodies or the antigen binding fragments thereof, an expression vector and a host cell for expressing the antibodies or the antigen binding fragments thereof, and therapeutic and diagnostic uses of the antibodies.
    Type: Application
    Filed: July 14, 2020
    Publication date: November 17, 2022
    Applicants: SHANGHAI JUNSHI BIOSCIENCES CO., LTD., SUZHOU JUNMENG BIOSCIENCES CO., LTD.
    Inventors: Qin MENG, Jian YAO, Hui FENG, Sheng YAO, Hai WU
  • Patent number: 11267890
    Abstract: An antibody or a functional fragment thereof that specifically bind to PD-L1 with high affinity, a nucleic acid molecule that encodes said antibody or the functional fragment thereof, an expression vector and a host cell for use in expressing said antibody or the functional fragment thereof, and a method for producing said antibody or the functional fragment thereof. An immunoconjugate and a pharmaceutical composition containing said antibody or the functional fragment thereof, and a method for using said antibody or the functional fragment thereof to enhance the function of a T cell so as to up-regulate a cell-mediated immune response, for use in treating diseases caused by T cell dysfunction.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: March 8, 2022
    Assignees: SHANGHAI JUNSHI BIOSCIENCES INC., SUZHOU JUNMENG BIOSCIENCES CO., LTD.
    Inventors: Hai Wu, Sheng Yao, Yuehua Zhou, Jian Yao, Dan Meng, Hui Feng
  • Patent number: 10858447
    Abstract: The present invention provides an antibody or a functional fragment thereof that specifically binds to Proprotein convertase subtilisin/kexin type 9 (PCSK9) with high affinity, also provides a nucleic acid molecule encoding the antibody of the invention or the functional fragment thereof, for expressing an expression vector and a host cell of the antibody or the functional fragment thereof, and also provides a method for producing the antibody or the functional fragment thereof. The present invention provides that the antibody or the functional fragment thereof is used for treating diseases such as dyslipidemia.
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: December 8, 2020
    Assignees: Junshi Biosciences Co., Ltd., Junmeng Biosciences Co., Ltd.
    Inventors: Hai Wu, Bo Chen, Hui Feng, Sheng Yao, Jian Yao, Hongchuan Liu, Libo Zhang, Jing Zhang, Dan Meng
  • Patent number: 10815302
    Abstract: This invention provides antibodies or functional fragments thereof that bind to PD-1 with high affinity. The invention provides nucleic acid molecules encoding the antibodies or the fragments thereof according to the present invention, expression vectors and host cells for expressing the antibodies or the functional fragments thereof according to the present invention, as well as methods for producing the antibodies or the functional fragments thereof according to the present invention. The present invention also provides immunoconjugates and pharmaceutical compositions comprising the antibodies or the functional fragments thereof according to the present invention. The present invention additionally provides methods for treating a plurality of diseases (comprising cancers, infectious diseases and inflammatory diseases) by using the antibodies or the functional fragments thereof disclosed herein.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: October 27, 2020
    Assignees: Shanghai Junshi Biosciences Co., Ltd., Junmeng Biosciences Co., Ltd.
    Inventors: Bo Chen, Hai Wu, Hui Feng
  • Patent number: 10066013
    Abstract: This invention provides antibodies or functional fragments thereof that bind to PD-1 with high affinity. The invention provides nucleic acid molecules encoding the antibodies or the fragments thereof according to the present invention, expression vectors and host cells for expressing the antibodies or the functional fragments thereof according to the present invention, as well as methods for producing the antibodies or the functional fragments thereof according to the present invention. The present invention also provides immunoconjugates and pharmaceutical compositions comprising the antibodies or the functional fragments thereof according to the present invention. The present invention additionally provides methods for treating a plurality of diseases (comprising cancers, infectious diseases and inflammatory diseases) by using the antibodies or the functional fragments thereof disclosed herein.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: September 4, 2018
    Assignees: SHANGHAI JUNSHI BIOSCIENCES INC., JUNMENG BIOSCIENCES CO., LTD.
    Inventors: Bo Chen, Hai Wu, Hui Feng